TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...
Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain. The Food and Drug Administration (FDA) has expanded the ...
Experts are already treating addicted people with at-home neuromodulation devices to control cravings, and the future is ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
Munich, Germany and Riyadh, Saudi Arabia - neurocare group AG ("neurocare” or the "Company”), a best practice platform for ...
Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...
83% of patients who complete Transcranial Magnetic Stimulation treatment experience measurable relief and 62% experience full remission of depression symptoms The expanded label positions Neuronetics' ...
The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results